Eli Lilly (LLY)

Even a small share of the weight loss drug market could lead to a substantial increase in the company's share price.

LifeMD (NASDAQ:LFMD) lowered its full-year revenue and adjusted EBITDA outlook after third-quarter sales fell short of its forecast, as the virtual healthcare company cut marketing spending and took longer than expected to launch branded GLP-1 fulfillment arrangements. Revenue for the quarter ended

The world's largest healthcare company is making shrewd investments in its future.

Lilly's experimental GLP-1 is effective in treating osteoarthritic knee pain.

Hims & Hers stock sank after a Q3 earnings and revenue miss, lower EBITDA guidance, subscriber declines, and an expanding FTC lawsuit over privacy and billing practices.

Novo Nordisk lived up to expectations for its Wegovy pill in the third quarter, but it still has more work ahead.

These drugmakers offer very different risk-reward profiles.

iShares offers lower fees and smoother returns, while First Trust provides concentrated biotech exposure with higher growth potential.

Eli Lilly's sales jumped 44.7% last year, while Johnson & Johnson's steadier profile raises a different question for cautious portfolios.

It takes a slightly different mindset when you're investing for a longer time horizon.

These stocks have been going in different directions over the past year, but that trend may not necessarily continue.

Management is betting that a lighter marketing push now sets Hims & Hers up for the January weight-loss surge, but it's unclear whether lost subscribers will return.

The upside outweighs the inevitable volatility.

The healthcare stock has soared past the S&P 500 this year as its results have been strong in recent quarters.

As tech stocks sell off, the ProShares S&P 500 ex-Technology ETF (SPXT) offers reduced AI exposure, but its mega-cap holdings, light liquidity, and trailing returns temper its appeal.

The companies are competing in the weight loss drug market.

One of these stocks is up 265% over the past year -- and its shares don't seem wildly overvalued, either.

Novo Nordisk is looking to build a volume-driven business, but the successful launch of the Wegovy pill is just the first step.

Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too.

The stock is expensive, but the potential market for GLP-1 drugs is likely much larger than forecast.

XBI delivered stronger 1-year returns at 45%, but IYH's diversified portfolio weathered volatility far better, with a maximum drawdown of just 17.9% versus 53.2%.

Eli Lilly could thrive even as competition in the weight-loss market intensifies.

Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the company's obesity drugs.

They have both outperformed the broader equity market over the long run.